Acorda gains pulmonary drug delivery tech in $525 Civitas deal

September 25, 2014 11:25 AM

15 0

Acorda has gained a pulmonary delivery technology and a GMP manufacturing site in Massachusetts along with a Parkinson’s disease candidate in its $525m (€410m) acquisition of Civitas.

New York-based Acorda Therapeutics announced yesterday it is acquiring Civitas Therapeutics, obtaining the worldwide rights to the CVT-301 compound currently in Phase III trials for OFF episodes of Parkinson’s disease.

Read more

To category page